BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Calcium\, magnesium\, potassium and sodium oxybates (Xywav) re
 adouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Calcium\, magnesium\, potassium and sodiu
 m oxybates (Xywav)\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05837091-11034@assetmemo.bio
DTSTAMP:20261121T010022Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Calcium\, magnesium\, potassium and sodium oxybates (Xywav): Phase 
 4 readout est. (NCT05837091)
DESCRIPTION:Calcium\, magnesium\, potassium and sodium oxybates (Xywav)\, p
 hase 4\, Idiopathic Hypersomnia.\nStudy: Low Sodium Oxybate in Patients Wi
 th Idiopathic Hypersomnia\nEstimated primary completion: 29 January 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/calcium-magnesium-pot
 assium-and-sodium-oxybates-xywav#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05837091
URL:https://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxyba
 tes-xywav#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06421532-11034@assetmemo.bio
DTSTAMP:20261121T010022Z
DTSTART;VALUE=DATE:20270927
DTEND;VALUE=DATE:20270928
SUMMARY:Calcium\, magnesium\, potassium and sodium oxybates (Xywav): Phase 
 2 readout est. (NCT06421532)
DESCRIPTION:Calcium\, magnesium\, potassium and sodium oxybates (Xywav)\, p
 hase 2.\nStudy: Stimulating Amyloid Clearance in Cerebral Amyloid Angiopat
 hy\nEstimated primary completion: 27 September 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxy
 bates-xywav#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06421532
URL:https://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxyba
 tes-xywav#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625280-11034@assetmemo.bio
DTSTAMP:20261121T010022Z
DTSTART;VALUE=DATE:20271223
DTEND;VALUE=DATE:20271224
SUMMARY:Calcium\, magnesium\, potassium and sodium oxybates (Xywav): Phase 
 3 readout est. (NCT07625280)
DESCRIPTION:Calcium\, magnesium\, potassium and sodium oxybates (Xywav)\, p
 hase 3\, Narcolepsy.\nStudy: A Study Evaluating the Efficacy and Safety of
  Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH\nE
 stimated primary completion: 23 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxybates-
 xywav#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07625280
URL:https://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxyba
 tes-xywav#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06950281-11034@assetmemo.bio
DTSTAMP:20261121T010022Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Calcium\, magnesium\, potassium and sodium oxybates (Xywav): Phase 
 2 readout est. (NCT06950281)
DESCRIPTION:Calcium\, magnesium\, potassium and sodium oxybates (Xywav)\, p
 hase 2.\nStudy: Efficacy\, Safety and Tolerability of Low Sodium Oxybate f
 or Nocturnal Cluster Headache Attacks\nEstimated primary completion: Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/calcium-mag
 nesium-potassium-and-sodium-oxybates-xywav#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06950281
URL:https://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxyba
 tes-xywav#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
